Skip to main content

Invivyd Inc

For the period ended Mar 31, 2024. Filed May 9, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 9, 2024

IVVD$0.57-3.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

(In thousands)

Three Months Ended March 31,Three Months Ended March 31,
20242023
Cash flows from operating activities:
Net loss$(43,496)$(35,321)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense5,3795,400
Net amortization of premiums and accretion of discounts on marketable securities—(2,543)
Amortization of operating lease right-of-use assets402379
Depreciation expense122120
Changes in operating assets and liabilities:
Inventory(104)—
Prepaid expenses and other current assets4,015(6,269)
Other non-current assets(1,682)(100)
Accounts payable(6,785)4,430
Accrued expenses(6,964)(6,909)
Operating lease liabilities(406)(381)
Other current liabilities513
Other non-current liabilities(700)—
Net cash used in operating activities(50,214)(41,181)
Cash flows from investing activities:
Maturities of marketable securities—75,660
Purchases of property and equipment(140)(624)
Net cash (used in) provided by investing activities(140)75,036
Cash flows from financing activities:
Proceeds from exercises of stock options—459
Proceeds from issuance of common stock under the employee stock purchase plan8983
Proceeds from issuance of common stock, net of issuance costs39,285—
Payments for offering costs(273)—
Net cash provided by financing activities39,101542
Net (decrease) increase in cash and cash equivalents(11,253)34,397
Cash and cash equivalents at beginning of period200,64192,076
Cash and cash equivalents at end of period$189,388$126,473
Supplemental disclosure of cash flow information
Deferred offering costs in accrued expenses$133$—
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.